Last reviewed · How we verify
Dupilumab Prefilled Syringe
Dupilumab Prefilled Syringe is a Monoclonal antibody; IL-4 receptor antagonist Biologic drug developed by Jonathan A. Bernstein, MD. It is currently FDA-approved for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps. Also known as: dupixent, DUPIXENT.
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation.
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.
At a glance
| Generic name | Dupilumab Prefilled Syringe |
|---|---|
| Also known as | dupixent, DUPIXENT |
| Sponsor | Jonathan A. Bernstein, MD |
| Drug class | Monoclonal antibody; IL-4 receptor antagonist |
| Target | IL-4 receptor alpha (IL-4Rα) |
| Modality | Biologic |
| Therapeutic area | Immunology; Allergy/Atopy |
| Phase | FDA-approved |
Mechanism of action
By antagonizing IL-4 receptor alpha, dupilumab suppresses the IL-4 and IL-13 pathways that drive type 2 inflammatory responses. This reduces production of IgE antibodies, eosinophil recruitment, and other hallmarks of allergic and atopic inflammation. The mechanism is effective across multiple type 2-mediated conditions including atopic dermatitis, asthma, and allergic rhinitis.
Approved indications
- Moderate-to-severe atopic dermatitis
- Moderate-to-severe asthma with type 2 inflammation
- Chronic rhinosinusitis with nasal polyps
- Allergic rhinitis
- Eosinophilic esophagitis
Common side effects
- Injection site reactions
- Conjunctivitis
- Headache
- Nasopharyngitis
- Herpes simplex infection
Key clinical trials
- A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma (PHASE3)
- Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (PHASE3)
- Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease (PHASE2)
- Dupilumab in the Treatment of Keloids (PHASE4)
- Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) (PHASE2)
- Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP (PHASE4)
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® (PHASE1)
- Dupilumab for Prevention of Recurrence of CRSwNP After ESS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab Prefilled Syringe CI brief — competitive landscape report
- Dupilumab Prefilled Syringe updates RSS · CI watch RSS
- Jonathan A. Bernstein, MD portfolio CI
Frequently asked questions about Dupilumab Prefilled Syringe
What is Dupilumab Prefilled Syringe?
How does Dupilumab Prefilled Syringe work?
What is Dupilumab Prefilled Syringe used for?
Who makes Dupilumab Prefilled Syringe?
Is Dupilumab Prefilled Syringe also known as anything else?
What drug class is Dupilumab Prefilled Syringe in?
What development phase is Dupilumab Prefilled Syringe in?
What are the side effects of Dupilumab Prefilled Syringe?
What does Dupilumab Prefilled Syringe target?
Related
- Drug class: All Monoclonal antibody; IL-4 receptor antagonist drugs
- Target: All drugs targeting IL-4 receptor alpha (IL-4Rα)
- Manufacturer: Jonathan A. Bernstein, MD — full pipeline
- Therapeutic area: All drugs in Immunology; Allergy/Atopy
- Indication: Drugs for Moderate-to-severe atopic dermatitis
- Indication: Drugs for Moderate-to-severe asthma with type 2 inflammation
- Indication: Drugs for Chronic rhinosinusitis with nasal polyps
- Also known as: dupixent, DUPIXENT
- Compare: Dupilumab Prefilled Syringe vs similar drugs
- Pricing: Dupilumab Prefilled Syringe cost, discount & access